269 related articles for article (PubMed ID: 24252210)
1. The resistance mechanisms of proteasome inhibitor bortezomib.
Lü S; Wang J
Biomark Res; 2013 Mar; 1(1):13. PubMed ID: 24252210
[TBL] [Abstract][Full Text] [Related]
2. Molecular basis of bortezomib resistance: proteasome subunit beta5 (PSMB5) gene mutation and overexpression of PSMB5 protein.
Oerlemans R; Franke NE; Assaraf YG; Cloos J; van Zantwijk I; Berkers CR; Scheffer GL; Debipersad K; Vojtekova K; Lemos C; van der Heijden JW; Ylstra B; Peters GJ; Kaspers GL; Dijkmans BA; Scheper RJ; Jansen G
Blood; 2008 Sep; 112(6):2489-99. PubMed ID: 18565852
[TBL] [Abstract][Full Text] [Related]
3. Point mutation of the proteasome beta5 subunit gene is an important mechanism of bortezomib resistance in bortezomib-selected variants of Jurkat T cell lymphoblastic lymphoma/leukemia line.
Lü S; Yang J; Song X; Gong S; Zhou H; Guo L; Song N; Bao X; Chen P; Wang J
J Pharmacol Exp Ther; 2008 Aug; 326(2):423-31. PubMed ID: 18502982
[TBL] [Abstract][Full Text] [Related]
4. Interferon-γ-induced upregulation of immunoproteasome subunit assembly overcomes bortezomib resistance in human hematological cell lines.
Niewerth D; Kaspers GJ; Assaraf YG; van Meerloo J; Kirk CJ; Anderl J; Blank JL; van de Ven PM; Zweegman S; Jansen G; Cloos J
J Hematol Oncol; 2014 Jan; 7():7. PubMed ID: 24418325
[TBL] [Abstract][Full Text] [Related]
5. Inactivating PSMB5 mutations and P-glycoprotein (multidrug resistance-associated protein/ATP-binding cassette B1) mediate resistance to proteasome inhibitors: ex vivo efficacy of (immuno)proteasome inhibitors in mononuclear blood cells from patients with rheumatoid arthritis.
Verbrugge SE; Assaraf YG; Dijkmans BA; Scheffer GL; Al M; den Uyl D; Oerlemans R; Chan ET; Kirk CJ; Peters GJ; van der Heijden JW; de Gruijl TD; Scheper RJ; Jansen G
J Pharmacol Exp Ther; 2012 Apr; 341(1):174-82. PubMed ID: 22235146
[TBL] [Abstract][Full Text] [Related]
6. Proteasome-based mechanisms of intrinsic and acquired bortezomib resistance in non-small cell lung cancer.
de Wilt LH; Jansen G; Assaraf YG; van Meerloo J; Cloos J; Schimmer AD; Chan ET; Kirk CJ; Peters GJ; Kruyt FA
Biochem Pharmacol; 2012 Jan; 83(2):207-17. PubMed ID: 22027222
[TBL] [Abstract][Full Text] [Related]
7. Different mutants of PSMB5 confer varying bortezomib resistance in T lymphoblastic lymphoma/leukemia cells derived from the Jurkat cell line.
Lü S; Yang J; Chen Z; Gong S; Zhou H; Xu X; Wang J
Exp Hematol; 2009 Jul; 37(7):831-7. PubMed ID: 19426847
[TBL] [Abstract][Full Text] [Related]
8. Antileukemic activity and mechanism of drug resistance to the marine Salinispora tropica proteasome inhibitor salinosporamide A (Marizomib).
Niewerth D; Jansen G; Riethoff LF; van Meerloo J; Kale AJ; Moore BS; Assaraf YG; Anderl JL; Zweegman S; Kaspers GJ; Cloos J
Mol Pharmacol; 2014 Jul; 86(1):12-9. PubMed ID: 24737138
[TBL] [Abstract][Full Text] [Related]
9. Overexpression of the PSMB5 gene contributes to bortezomib resistance in T-lymphoblastic lymphoma/leukemia cells derived from Jurkat line.
Lü S; Chen Z; Yang J; Chen L; Gong S; Zhou H; Guo L; Wang J
Exp Hematol; 2008 Oct; 36(10):1278-84. PubMed ID: 18562081
[TBL] [Abstract][Full Text] [Related]
10. Regulation of PSMB5 protein and β subunits of mammalian proteasome by constitutively activated signal transducer and activator of transcription 3 (STAT3): potential role in bortezomib-mediated anticancer therapy.
Vangala JR; Dudem S; Jain N; Kalivendi SV
J Biol Chem; 2014 May; 289(18):12612-22. PubMed ID: 24627483
[TBL] [Abstract][Full Text] [Related]
11. Proteasome Subunits Differentially Control Myeloma Cell Viability and Proteasome Inhibitor Sensitivity.
Shi CX; Zhu YX; Bruins LA; Bonolo de Campos C; Stewart W; Braggio E; Stewart AK
Mol Cancer Res; 2020 Oct; 18(10):1453-1464. PubMed ID: 32561655
[TBL] [Abstract][Full Text] [Related]
12. Potent anti-tumor activity of a syringolin analog in multiple myeloma: a dual inhibitor of proteasome activity targeting β2 and β5 subunits.
Yoshida T; Ri M; Kanamori T; Aoki S; Ashour R; Kinoshita S; Narita T; Totani H; Masaki A; Ito A; Kusumoto S; Ishida T; Komatsu H; Kitahata S; Chiba T; Ichikawa S; Iida S
Oncotarget; 2018 Feb; 9(11):9975-9991. PubMed ID: 29515784
[TBL] [Abstract][Full Text] [Related]
13. An investigation of the mechanisms underlying the proteasome inhibitor bortezomib resistance in PC3 prostate cancer cell line.
Yerlikaya A; Okur E
Cytotechnology; 2020 Feb; 72(1):121-130. PubMed ID: 31863311
[TBL] [Abstract][Full Text] [Related]
14. MiR-383 sensitizes osteosarcoma cells to bortezomib treatment via down-regulating PSMB5.
Wang H; Bai C; Dang X; Wang H
Mol Biol Rep; 2024 Jan; 51(1):170. PubMed ID: 38252234
[TBL] [Abstract][Full Text] [Related]
15. [Effects of PSMB5 on proliferation and bortezomib chemo-resistance in human myeloma cells and its related molecular mechanisms].
Mo HM; Wu QY; Han DY; Liu R; Ma X; Zhou P; Xu KL
Zhonghua Xue Ye Xue Za Zhi; 2017 Dec; 38(12):1053-1057. PubMed ID: 29365400
[No Abstract] [Full Text] [Related]
16. Proteasome inhibition and mechanism of resistance to a synthetic, library-based hexapeptide.
Oerlemans R; Berkers CR; Assaraf YG; Scheffer GL; Peters GJ; Verbrugge SE; Cloos J; Slootstra J; Meloen RH; Shoemaker RH; Dijkmans BAC; Scheper RJ; Ovaa H; Jansen G
Invest New Drugs; 2018 Oct; 36(5):797-809. PubMed ID: 29442210
[TBL] [Abstract][Full Text] [Related]
17. Bortezomib-resistant myeloma cell lines: a role for mutated PSMB5 in preventing the accumulation of unfolded proteins and fatal ER stress.
Ri M; Iida S; Nakashima T; Miyazaki H; Mori F; Ito A; Inagaki A; Kusumoto S; Ishida T; Komatsu H; Shiotsu Y; Ueda R
Leukemia; 2010 Aug; 24(8):1506-12. PubMed ID: 20555361
[TBL] [Abstract][Full Text] [Related]
18. Novel mechanism of drug resistance to proteasome inhibitors in multiple myeloma.
Zhou J; Chng WJ
World J Clin Oncol; 2019 Sep; 10(9):303-306. PubMed ID: 31572666
[TBL] [Abstract][Full Text] [Related]
19. Anti-leukemic activity and mechanisms underlying resistance to the novel immunoproteasome inhibitor PR-924.
Niewerth D; van Meerloo J; Jansen G; Assaraf YG; Hendrickx TC; Kirk CJ; Anderl JL; Zweegman S; Kaspers GJ; Cloos J
Biochem Pharmacol; 2014 May; 89(1):43-51. PubMed ID: 24552657
[TBL] [Abstract][Full Text] [Related]
20. Molecular mechanisms of acquired proteasome inhibitor resistance.
Kale AJ; Moore BS
J Med Chem; 2012 Dec; 55(23):10317-27. PubMed ID: 22978849
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]